The Fat-Bloated Brain Cells That Make Multiple Sclerosis Worse

Introduction: an unexpected clue in patients' brains

A discovery born from careful observation of brain tissue

Dutch researchers have just uncovered a surprising clue that could explain why multiple sclerosis progresses rapidly in some patients while remaining stable in others for years. Examining brain tissue from people with severe forms of the disease, the team observed an unusual number of immune cells swollen with fat droplets after ingesting damaged myelin.

These cells, dubbed foamy microglia for their bubble-like appearance under the microscope, appear to flip from a repair role to a destructive one, fueling inflammation rather than containing it. It's this flip, precisely documented, that lies at the heart of the discovery published in the journal Nature Neuroscience.

Why this lead changes how we understand the disease

Multiple sclerosis is an autoimmune disease that attacks the myelin sheath surrounding nerve fibers, causing lesions visible on magnetic resonance imaging. Until now, much of the research focused on the inflammatory response itself, without always explaining why some lesions heal while others keep expanding for years.

This new study suggests the process is more complex than simple inflammation: a mechanism that initially protects the brain can, when overwhelmed, turn against the patient and perpetuate the damage instead of repairing it.

The normal role of microglia in a healthy brain

Cleanup cells essential to proper brain function

In a healthy brain, microglia act as immune sentinels, continuously patrolling tissue to detect and clear cellular debris, pathogens and remnants of damaged myelin. This cleanup function is essential to maintaining the integrity of the central nervous system throughout life.

These cells also participate in tissue repair, fostering an environment conducive to regenerating nerve connections after an injury or localized inflammation. Their presence is therefore, under normal circumstances, a positive sign rather than a cause for concern among neurologists studying brain lesions.

When the cleanup system becomes overwhelmed

The problem arises when microglia absorb an amount of damaged myelin that exceeds their natural processing capacity. According to the researchers, these cells then become literally saturated with fat, a state that compromises their ability to effectively carry out their original repair mission.

This overload gradually turns protective cells into aggravating factors, a role reversal that could explain why some multiple sclerosis lesions never fully heal and instead keep expanding over time.

The hard data behind the discovery

A study built on tissue from numerous donors

Researchers at the Netherlands Institute for Neuroscience, working with Leiden University, Utrecht University and the Netherlands Brain Bank, analyzed brain tissue from 28 deceased patients who had donated their brains to research. This bank of samples allowed for an in-depth examination combining gene activity, proteins and lipids present in each lesion.

A follow-up analysis, conducted on a larger cohort of 250 donors with secondary progressive multiple sclerosis, confirmed the correlation between the proportion of lesions containing foamy microglia and faster progression of disability over the course of patients' lives.

A consistent statistical link between severity and foamy cells

According to researcher Daan van der Vliet, cited in the published results, patients with large numbers of these foamy microglia more frequently experienced a severe course of their disease. Lesions made up mostly of non-foamy microglia, by contrast, were not associated with this accelerated progression.

This distinction matters, since it suggests that it's not simply the presence of inflammation that counts, but rather the specific nature of the cells involved and their state of lipid overload at the time of observation.

The molecular mechanism identified by researchers

An enzyme at the heart of the inflammatory switch

The team identified increased activity of an enzyme called MAGL in foamy microglia. This enzyme breaks down fatty molecules into oxylipins, chemical signals that regulate inflammation and communication between cells of the immune system.

Lesions containing large numbers of foamy microglia were particularly enriched in these oxylipins linked to prolonged inflammatory activity, reinforcing the hypothesis of a vicious cycle in which fat overload directly fuels chronic inflammation that is hard to shut down.

A lead successfully tested in an animal model

Notably, blocking the MAGL enzyme in an animal model replicating multiple sclerosis-type brain damage led to signs of neurological repair usually absent in this experimental model. This result suggests that targeting this molecular pathway could one day help unlock the brain's natural capacity for repair.

An experimental treatment specifically targeting MAGL is, in fact, already in clinical development, with trials being conducted in collaboration with pharmaceutical company Roche, according to information published about this research.

Hope for a biomarker to anticipate disease progression

Measurable traces in cerebrospinal fluid

Researchers found that oxylipin levels in cerebrospinal fluid closely matched the proportion of foamy microglia observed in patients' brain lesions. This correlation opens the door to a concrete diagnostic tool potentially accessible without needing a brain biopsy.

Such a biomarker, if confirmed by further studies, would allow doctors to identify earlier which patients are at risk of rapid decline, even before obvious clinical signs of severe disease progression appear.

Toward more personalized medicine for progressive patients

According to remarks attributed to the lead researcher, this advance opens the possibility of developing tools to determine which treatment would work best for each patient, based on their specific biological profile rather than a single standardized approach for all cases of progressive multiple sclerosis.

This approach fits into a broader trend in precision medicine, which seeks to tailor neurological treatments to individual biological characteristics rather than applying generic protocols uniformly.

The methodological limits the researchers acknowledge themselves

A study built on post-mortem tissue

The study's authors acknowledge an important limitation: all of the analyses were conducted on brain tissue from deceased donors, making it impossible to directly observe how these cells behave in living patients over time. This methodological constraint is common in research on neurodegenerative diseases, but it limits the scope of the conclusions.

It therefore remains necessary to confirm these observations through longitudinal studies in living patients, particularly using advanced imaging techniques or repeated analyses of cerebrospinal fluid as the disease progresses.

Causation still to be more firmly established

While the correlation between foamy microglia and severe progression appears statistically solid, it does not by itself prove a direct causal link. The researchers themselves describe a hypothesis that needs further testing, particularly to rule out the possibility that these cells are merely a marker of already-severe inflammation rather than an active cause of its worsening.

This scientific caution, far from weakening the discovery, actually strengthens its credibility among the community of neurologists specializing in multiple sclerosis.

A broader context: other leads on cellular energy

Earlier work on mitochondria and cerebrospinal fluid

This discovery about foamy microglia adds to other research leads explored in recent years on the cellular energy mechanisms involved in progressive multiple sclerosis. Work carried out with the NYSCF Research Institute, among others, had already suggested that the cerebrospinal fluid of progressive patients could impair the function of mitochondria, the energy-producing structures within brain cells.

This earlier research had identified a possible role for ceramides, fatty molecules present in excess in the cerebrospinal fluid of certain patients, capable of disrupting cells' ability to properly metabolize glucose and produce energy.

A convergence of leads around fat metabolism

The convergence between these different lines of research is striking: whether we're talking about foamy microglia or ceramide-related mitochondrial dysfunction, fat metabolism appears to play a central and underestimated role in the progression of multiple sclerosis, beyond the classic autoimmune dimension alone.

According to several researchers in the field, this convergence could pave the way for combined therapeutic strategies, simultaneously targeting several aspects of brain lipid metabolism rather than a single isolated molecular pathway.

What this means concretely for patients today

No immediate treatment, but a clear trajectory

It's important to be honest with patients and their families: this discovery does not lead to an immediately available treatment. Clinical trials targeting MAGL are still at early stages, and drug development, from basic research to regulatory approval, generally takes many years.

What this research does offer, however, is a clear scientific trajectory and a more refined understanding of the mechanisms at play, which historically constitutes the essential first step toward developing effective therapies in the field of neurodegenerative diseases.

The importance of staying connected to patient support organizations

Patients with progressive multiple sclerosis, who often face a lack of therapeutic options, have every interest in staying informed about these advances through recognized organizations like the National MS Society, which closely tracks research developments and regularly communicates about ongoing clinical trials.

This informed vigilance, without giving in to excessive optimism, allows patients to have knowledgeable discussions with their medical teams about clinical research options potentially accessible given their specific profile.

The role of major international scientific collaborations

Research made possible by brain tissue donations

This advance would not have been possible without the generosity of 28 donors and their families, who agreed to donate brain tissue to research through the Netherlands Brain Bank. This type of donation, often unrecognized by the general public, constitutes an irreplaceable resource for studying complex neurodegenerative diseases.

Without these contributions to science, it would simply be impossible to examine in detail the molecular composition of human brain lesions, an examination that cannot be faithfully replicated by animal models alone, however useful they may otherwise be.

Basic research funding under scrutiny

This study was supported by two Dutch basic research programs, the Institute for Chemical Immunology and the Institute for Chemical NeuroScience, illustrating the importance of stable public funding for enabling this kind of long-term basic research, whose clinical payoffs only become visible years later.

This point deserves to be highlighted at a time when basic research budgets are the subject of recurring debate in several Western countries, caught between budgetary pressures and the need to keep funding science whose concrete benefits are not always immediate.

How this discovery fits into the history of MS research

Decades of research centered on autoimmunity

For decades, research on multiple sclerosis has largely focused on the disease's autoimmune dimension, seeking to understand why the immune system mistakenly attacks the myelin of the central nervous system. This approach has enabled the development of several effective treatments for relapsing-remitting forms of the disease.

These immunomodulatory treatments, while effective at slowing relapses, remain largely insufficient, however, for progressive forms of multiple sclerosis, a finding that has pushed research to explore other complementary mechanisms, such as that of foamy microglia.

A new generation of metabolic therapeutic leads

This discovery therefore fits into a broader shift in neurological research, which is now paying closer attention to the metabolic and energy-related mechanisms of brain cells, complementing the classic immunological approaches that have dominated the field for decades.

This diversification of research leads is generally seen by specialists as a sign of scientific maturity, rather than an abandonment of previously acquired knowledge about the disease's autoimmune dimension.

The next steps expected by the scientific community

Confirming results in larger, more diverse cohorts

The logical next step for the scientific community is to confirm these results in larger, more diverse patient cohorts, including different geographic origins and different subtypes of progressive multiple sclerosis, in order to check the robustness of this correlation between foamy microglia and disease severity.

Prospective studies, following living patients over time rather than post-mortem tissue, will also be needed to more solidly establish the causal link between microglial lipid overload and the clinical worsening observed in some patients.

Advancing clinical trials targeting the MAGL pathway

On the therapeutic front, the community's attention will turn to the results of clinical trials targeting the MAGL pathway, currently in development in collaboration with the pharmaceutical industry. These trials, if they confirm a tangible clinical benefit, could represent the first concrete application of this basic discovery in living patients.

The road remains long between identifying a mechanism and getting an approved treatment, but the scientific community generally views this kind of precise molecular lead as promising for further clinical development.

The questions this research still leaves open

Why do some patients develop more foamy microglia than others

One central question remains without a clear answer at this stage: why do some patients develop a much higher proportion of foamy microglia than others, for an apparently similar level of myelin damage. Genetic, environmental or lifestyle-related factors could play a role, but this remains to be explored.

Answering this question could eventually pave the way for prevention strategies rather than mere treatment once lipid overload has already taken hold in affected patients' brains.

The possible role of diet and general metabolism

Some researchers in the field are also asking about the possible role of broader metabolic factors, such as a patient's diet or overall lipid metabolism, in the propensity of microglia to become foamy. This lead, however, remains speculative and would require dedicated studies to be confirmed or ruled out.

Without jumping to hasty conclusions about unproven lifestyle changes, this question illustrates just how much research on progressive multiple sclerosis remains a rapidly evolving field, with more open questions than established certainties.

The indirect voice of a waiting patient community

A disease affecting hundreds of thousands of people

Multiple sclerosis affects hundreds of thousands of people worldwide, with progressive forms representing a particularly underserved subgroup given the lack of effective therapeutic options. Every scientific advance of this kind is closely followed by patient associations, which relay the information to their members with the necessary caution.

This patient community, often facing silent progression that is hard to slow, represents the audience most directly affected by this kind of basic discovery, even though concrete clinical benefits will only materialize years from now.

The delicate balance between hope and realism

Communicating about this kind of discovery requires a delicate balance between legitimate hope and scientific realism. Patients deserve to know about research advances that directly concern them, without being promised treatments that may never materialize in their current form.

This is the balance the researchers themselves appear to have sought to maintain in their public communications about this discovery, insisting both on the potential of the lead and on the many steps that remain to be taken.

What this discovery changes for pharmaceutical research

Growing industry interest in metabolic targets

The involvement of a pharmaceutical partner as large as Roche in developing a treatment targeting MAGL reflects growing industry interest in metabolic targets for treating neurodegenerative diseases, a field long dominated by purely immunomodulatory approaches.

This shift reflects a broader trend observed across the pharmaceutical industry, where chronic neurological diseases are attracting growing investment as basic knowledge of their mechanisms advances.

The challenges of moving from lab to patient

Despite this enthusiasm, the path from a promising molecular target identified in the lab to an approved drug remains littered with regulatory and scientific obstacles. Many promising molecules at the preclinical stage fail during human trials, a useful reminder to temper expectations around this discovery.

Upcoming clinical trials will need to demonstrate not only measurable efficacy against disability progression, but also an acceptable safety profile for long-term use in patients with a chronic disease.

Conclusion: one more piece in a complex puzzle

A discovery that enriches without replacing existing knowledge

This discovery about foamy microglia does not replace decades of research into the autoimmune dimension of multiple sclerosis, but it considerably enriches our overall understanding of the disease, particularly for its hardest-to-treat progressive forms. It illustrates the biological complexity of a disease that keeps revealing new mechanisms after years of intensive study.

For researchers, this advance opens a new avenue of therapeutic exploration, centered on brain lipid metabolism, which will complement rather than replace the immunological approaches already available to patients.

What to remember in the months ahead

The coming months and years will be decisive in determining whether this lead holds up in larger cohorts and leads to concrete clinical applications, whether in the form of diagnostic biomarkers or treatments targeting the MAGL pathway. In the meantime, this discovery represents a solid, methodologically rigorous scientific advance that deserves to be followed with measured optimism by the patient and healthcare professional communities.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my limits in the face of medical science

I sign this piece as a columnist, not as a scientist or healthcare professional. My role is to make accessible a discovery published in a recognized scientific journal, drawing on research releases and specialized articles publicly available, without claiming medical expertise I do not possess.

I have no ties to the research institutions cited, nor to the pharmaceutical company mentioned in this article.

My method, and what I cannot guarantee

I cross-checked several specialized journalistic and scientific sources to write this piece, trying to faithfully represent the nuances and limitations expressed by the researchers themselves. I cannot guarantee that this therapeutic lead will result in an approved treatment, and I encourage any affected patient to discuss these advances with their medical team rather than rely solely on this article.

Sources

Primary sources

These fat-filled brain cells may be making multiple sclerosis worse — ScienceDaily, June 29, 2026

Abnormal fat in brain immune cells may help drive progressive MS — Multiple Sclerosis News Today, June 2, 2026

Health & Medicine News — ScienceDaily

Secondary sources

Lipids and microglia fuel chronic inflammation in multiple sclerosis — Immunopaedia

NYSCF Collaboration Finds Possible Mechanism Behind Tired Brain Cells in Progressive MS — NYSCF

National Multiple Sclerosis Society — patient resources